Print

ANYARA

A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. Hawkins R, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P, Karyakin O, Khasanov R, Hedlund G, Forsberg G, Nordle Ö, Eisen T. Clin Cancer Res. Feb 5, 2016.

Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α. Elkord E, Burt DJ, Sundstedt A, Nordle Ö, Hedlund G, Hawkins R. Oncotarget. 2015 Feb; 6(6): 4428–4439. doi: 10.18632/oncotarget.2922.

Naptumomab Estafenatox: targeted Immunotherapy with a Novel Immunotoxin. Eisen T, Hedlund G, Forsberg G, Hawkins R. Curr Oncol Rep (2014) 16:370. DOI 10.1007/s11912-013-0370-0.

The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity. Hedlund G, Eriksson H, Sundstedt A, Forsberg G, Jakobsen BK, Pumphrey N, Rödström K, Lindkvist-Petersson K, Björk P. PLoS ONE 8(10): e79082. doi:10.1371/journal.pone.0079082.

Monotherapeutically Nonactive CTLA-4 Blockade Results in Greatly Enhanced Antitumor Effects When Combined With Tumor-targeted Superantigens in a B16 Melanoma Model. Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G. J Immunother 2012 May, 35 (4): 344–353.

Tumor-Targeted Superantigens, in Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges. Hedlund G, Forsberg G, Nederman T, Sundstedt A, Dahlberg L, Tiensuu M, Nilsson, M. (ed S. R. Schmidt) 2013; p365-381, John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118354599.ch24

Naptumomab estafenatox: a new immunoconjugate. Robinson MK, Alpaugh KR, Borghaei H. Expert Opin Biol Ther. 2010;10:273-279. doi: 10.1517/14712590903575620

Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. Forsberg G, Skartved N-J, Wallén-Öhman M, Carlsson-Nyhlen H, Behm K, Hedlund G, Nederman T. J Immunother. 2010; 33:492-499. doi: 10.1097/CJI.0b013e3181d75820

Phase I dose escalation, pharmakokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non small-cell lung cancer. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. J Clin Oncol. 2009; 27: 4116-4123. doi: 10.1200/JCO.2008.20.2515.